Ocugen Secures Gene Therapy Licenses Ahead of Phase 3 Results
MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has secured a Middle East and North Africa licensing agreement worth up to $259 million in potential payments and received provisional regulatory approval …
Ocugen Secures Gene Therapy Licenses Ahead of Phase 3 Results Read More